Notice NOT-AT-17-009 from the NIH Guide for Grants and Contracts

Notice NOT-DA-17-023 from the NIH Guide for Grants and Contracts

Notice NOT-DA-17-022 from the NIH Guide for Grants and Contracts

Notice NOT-DA-17-021 from the NIH Guide for Grants and Contracts

Notice NOT-DA-17-020 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-CA-17-024 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits Small Business Innovation Research (SBIR) applications from small business concerns (SBCs) that seek additional funding to support the next stage of development for projects that were previously funded under SBIR or STTR Phase II awards from any Federal agency. Projects proposed in response to this FOA must be applicable to one of the following areas: (1) cancer therapeutics; (2) cancer imaging technologies, interventional devices, and/or in vivo diagnostics; or (3) in vitro and ex vivo cancer diagnostics and prognostics. The purpose of this FOA is to facilitate the transition of SBIR or STTR Phase II projects to the commercialization stage. This FOA is expected to promote partnerships between Federally-funded SBIR or STTR Phase II awardees and third-party investors and/or strategic partners to facilitate and accelerate the capital-intensive steps that are required to commercialize new products and services. Applicants must submit a Commercialization Plan, which should include details on any independent third-party investor funding that has already been secured or is anticipated during the Phase IIB Bridge Award project period. It is expected that the level of this independent third-party funding will be equal to or greater than the NCI funds being requested throughout the Phase IIB Bridge Award project period. Proposed projects may address preclinical and/or clinical stages of technology development. Clinical trials may be proposed as appropriate but are not required.

Notice NOT-HS-17-012 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-RM-17-010 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to invite applications (via limited competition) for SPARC Technologies to Understand the Control of Organ Function by the Peripheral Nervous System.

Funding Opportunity RFA-AR-18-005 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose preclinical studies to advance the development of biomarkers or treatments for rare musculoskeletal, rheumatic or skin diseases. Rare diseases have a prevalence of fewer than 200,000 affected individuals in the United States. Also eligible for potential funding through this initiative are studies of FDA-designated orphan products for musculoskeletal, rheumatic or skin diseases.

Notice NOT-OD-17-053 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-17-254 from the NIH Guide for Grants and Contracts. This FOA encourages applications for the Lasker Clinical Research Scholars Program for the purpose of supporting the research activities during the early stage careers of independent clinical researchers.

Funding Opportunity PAR-17-252 from the NIH Guide for Grants and Contracts. The primary objective of this FOA is to stimulate innovative Convergent Neuroscience (CN) approaches to establish causal and/or probabilistic linkages across contiguous levels of analysis (e.g., gene, molecule, cell, circuit, system, behavior) in an explanatory model of psychopathology. In particular, applicants should focus on how specific constituent biological processes at one level of analysis contribute to quantifiable properties at other levels, either directly or as emergent phenomena. Although not required, it is preferable that applications link at least three levels of analysis and include an emphasis on genetics. The projects under this FOA will develop novel methods, theories, and approaches through a CN team framework, bringing together highly synergistic inter/transdisciplinary teams from neuroscience and the orthogonal fields of the physical sciences (e.g., data/computational science, physics, engineering, mathematics). Successful teams will combine, expand upon, or develop conceptual frameworks and theoretical approaches, and build explanatory computational models that connect contiguous levels of analysis. Such frameworks, theories, and computational explanatory models should be validated through experimental approaches to elucidate biological underpinnings of complex behavioral (including cognitive and affective) outcomes in psychopathology. Additionally, a goal of this program is to advance research in CN by creating a shared community framework of resources which may be used by the broader research community to further research, as such, a successful team will be expected to have robust plan for sharing data and other resources.

Funding Opportunity PAR-17-253 from the NIH Guide for Grants and Contracts. The primary objective of this FOA is to stimulate innovative Convergent Neuroscience (CN) approaches to establish causal and/or probabilistic linkages across contiguous levels of analysis (e.g., gene, molecule, cell, circuit, system, behavior) in an explanatory model of psychopathology. In particular, applicants should focus on how specific constituent biological processes at one level of analysis contribute to quantifiable properties at other levels, either directly or as emergent phenomena. Although not required, it is preferable that applications link at least three levels of analysis and include an emphasis on genetics. The projects under this FOA will develop novel methods, theories, and approaches through a CN team framework, bringing together highly synergistic inter/transdisciplinary teams from neuroscience and the orthogonal fields of the physical sciences (e.g., data/computational science, physics, engineering, mathematics). Successful teams will combine, expand upon, or develop conceptual frameworks and theoretical approaches, and build explanatory computational models that connect contiguous levels of analysis. Such frameworks, theories, and computational explanatory models should be validated through experimental approaches to elucidate biological underpinnings of complex behavioral (including cognitive and affective) outcomes in psychopathology. Additionally, a goal of this program is to advance research in CN by creating a shared community framework of resources which may be used by the broader research community to further research, as such, a successful team will be expected to have a robust plan for sharing data and other resources.

Notice NOT-DK-17-011 from the NIH Guide for Grants and Contracts

Notice NOT-FD-17-007 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-DA-18-005 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to solicit applications proposing to test approaches for expanding medication assisted treatment (MAT) for opioid use disorder (OUD) in the general health care sector or linking individuals with OUDs who receive naloxone for the reversal of overdose to MAT in the context of states plans for use of the funds authorized under the 21st Century Cures Act.

Funding Opportunity PAR-17-251 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) is issued by the National Institute of Neurological Disorders and Stroke to enable submission of program project grant applications that propose to conduct innovative, interactive research to answer significant scientific questions that are important for the mission of NINDS, via a synergistic collaboration between outstanding scientists who might not otherwise collaborate. The program project grant is designed to support research in which the funding of several interdependent highly meritorious projects as a group offers significant scientific advantages over support of these same projects as individual research grants.

Funding Opportunity RFA-HL-18-020 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support integrated analysis of whole genome, large scale omic data generated by the NHLBIs Trans-Omics for Precision Medicine (TOPMed) program and associated phenotype and clinical data using systems approaches. Ultimately, these studies will advance our understanding of the molecular underpinnings of heart, lung, blood, and sleep disease.

Notice NOT-CA-17-049 from the NIH Guide for Grants and Contracts

Notice NOT-HD-17-011 from the NIH Guide for Grants and Contracts